C-fos-induced growth factor

C-fos induced growth factor (vascular endothelial growth factor D)
Available structures PDB Ortholog search: PDBe, RCSB List of PDB id codes 2XV7​
Identifiers
Symbols	FIGF ; VEGF-D; VEGFD
External IDs	OMIM: 300091 MGI: 108037 HomoloGene: 3288 GeneCards: FIGF Gene
Gene ontology Molecular function • platelet-derived growth factor receptor binding • vascular endothelial growth factor receptor binding • growth factor activity • chemoattractant activity • protein homodimerization activity • vascular endothelial growth factor receptor 3 binding Cellular component • extracellular region • extracellular space • membrane • platelet alpha granule lumen Biological process • angiogenesis • response to hypoxia • platelet degranulation • blood coagulation • cell proliferation • positive regulation of cell proliferation • cell differentiation • platelet activation • regulation of vascular endothelial growth factor receptor signaling pathway • positive regulation of interleukin-6 production • vascular endothelial growth factor receptor signaling pathway • positive chemotaxis • induction of positive chemotaxis • positive regulation of cell division • positive regulation of mast cell chemotaxis • response to interleukin-1 Sources: Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	2277	14205
Ensembl	ENSG00000165197	ENSMUSG00000031380
UniProt	O43915	P97946
RefSeq (mRNA)	NM_004469	NM_001308489
RefSeq (protein)	NP_004460	NP_001295418
Location (UCSC)	Chr X: 15.35 – 15.38 Mb	Chr X: 164.37 – 164.4 Mb
PubMed search

C-fos-induced growth factor (FIGF) (or vascular endothelial growth factor D, VEGF-D) is a vascular endothelial growth factor that in humans is encoded by the FIGF gene.^[1]

Function

The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor C.^[1]

Tumor metastasis to lymph nodes

Lymph node metastasis is very often associated with several types of human malignancies. Cancer cells’ journey to lymph node takes place largely through lymphatic tunnel located in and around of primary tumor. VEGF-D’s interactions with VEGFR-3 predominantly expressed in lymphatic vessels plays a key role in restructuring lymphatic channel and, hence, able to alter its functions related to fluid and cell transport along the conduits. VEGF-D has been established to be over-expressed in both tumor tissues and patients’ serum samples in several types of human cancer. In addition, VEGF-D expression has been implicated with increased incidence of regional lymph node metastasis. In experimental mice study, genetically modified tumor cell that was forced to produce VEGF-D protein have been established to boost up regional lymph nodes metastases.^[2]

References

1. "Entrez Gene: FIGF c-fos induced growth factor (vascular endothelial growth factor D)".
2. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG (Feb 2001). "VEGF-D promotes the metastatic spread of tumor cells via the lymphatics". Nature Medicine 7 (2): 186–91. doi:10.1038/84635. PMID 11175849.

Further reading

• Maruyama K, Sugano S (Jan 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene 138 (1-2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
• Orlandini M, Marconcini L, Ferruzzi R, Oliviero S (Oct 1996). "Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family". Proceedings of the National Academy of Sciences of the United States of America 93 (21): 11675–80. doi:10.1073/pnas.93.21.11675. PMC 38117. PMID 8876195.
• Yamada Y, Nezu J, Shimane M, Hirata Y (Jun 1997). "Molecular cloning of a novel vascular endothelial growth factor, VEGF-D". Genomics 42 (3): 483–8. doi:10.1006/geno.1997.4774. PMID 9205122.
• Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (Oct 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene 200 (1-2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
• Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA (Jan 1998). "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)". Proceedings of the National Academy of Sciences of the United States of America 95 (2): 548–53. doi:10.1073/pnas.95.2.548. PMC 18457. PMID 9435229.
• Rocchigiani M, Lestingi M, Luddi A, Orlandini M, Franco B, Rossi E, Ballabio A, Zuffardi O, Oliviero S (Jan 1998). "Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 between the PIGA and the GRPR genes". Genomics 47 (2): 207–16. doi:10.1006/geno.1997.5079. PMID 9479493.
• Stacker SA, Stenvers K, Caesar C, Vitali A, Domagala T, Nice E, Roufail S, Simpson RJ, Moritz R, Karpanen T, Alitalo K, Achen MG (Nov 1999). "Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers". The Journal of Biological Chemistry 274 (45): 32127–36. doi:10.1074/jbc.274.45.32127. PMID 10542248.
• Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K (Feb 2003). "Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up". Clinical Cancer Research 9 (2): 716–21. PMID 12576440.
• Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Umemoto M, Sakamoto T, Sato S, Mizunuma H, Smith SK (Jan 2003). "Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma". British Journal of Cancer 88 (2): 237–44. doi:10.1038/sj.bjc.6600701. PMC 2377043. PMID 12610509.
• Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Ylä-Herttuala S (May 2003). "VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses". Circulation Research 92 (10): 1098–106. doi:10.1161/01.RES.0000073584.46059.E3. PMID 12714562.
• Funaki H, Nishimura G, Harada S, Ninomiya I, Terada I, Fushida S, Tani T, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K (2003). "Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma". Oncology 64 (4): 416–22. doi:10.1159/000070301. PMID 12759540.
• Orlandini M, Semboloni S, Oliviero S (Nov 2003). "Beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability". The Journal of Biological Chemistry 278 (45): 44650–6. doi:10.1074/jbc.M304255200. PMID 12920128.
• McColl BK, Baldwin ME, Roufail S, Freeman C, Moritz RL, Simpson RJ, Alitalo K, Stacker SA, Achen MG (Sep 2003). "Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D". The Journal of Experimental Medicine 198 (6): 863–8. doi:10.1084/jem.20030361. PMC 2194198. PMID 12963694.
• Vlahakis NE, Young BA, Atakilit A, Sheppard D (Feb 2005). "The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1". The Journal of Biological Chemistry 280 (6): 4544–52. doi:10.1074/jbc.M412816200. PMC 1368959. PMID 15590642.
• Kurahara H, Takao S, Maemura K, Shinchi H, Natsugoe S, Aikou T (Dec 2004). "Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis". Clinical Cancer Research 10 (24): 8413–20. doi:10.1158/1078-0432.CCR-04-0379. PMID 15623620.
• Fink AM, Kaltenegger I, Schneider B, Frühauf J, Jurecka W, Steiner A (Dec 2004). "Serum level of VEGF-D in patients with primary lymphedema". Lymphology 37 (4): 185–9. PMID 15693535.
• Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M (Jan 2005). "Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease". Clinical Cancer Research 11 (2 Pt 1): 584–93. PMID 15701844.
• Yasuoka H, Nakamura Y, Zuo H, Tang W, Takamura Y, Miyauchi A, Nakamura M, Mori I, Kakudo K (Aug 2005). "VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma". Modern Pathology 18 (8): 1127–33. doi:10.1038/modpathol.3800402. PMID 15803188.